Amicus Therapeutics, Inc. (FOLD)

NASDAQ: FOLD · Real-Time Price · USD
8.52
-0.10 (-1.16%)
Mar 26, 2025, 4:00 PM EST - Market closed
Market Cap 2.62B
Revenue (ttm) 528.30M
Net Income (ttm) -56.11M
Shares Out 307.24M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE 297.49
Dividend n/a
Ex-Dividend Date n/a
Volume 2,666,506
Open 8.63
Previous Close 8.62
Day's Range 8.40 - 8.67
52-Week Range 8.40 - 12.65
Beta 0.69
Analysts Strong Buy
Price Target 17.00 (+99.53%)
Earnings Date May 8, 2025

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 31, 2007
Employees 499
Stock Exchange NASDAQ
Ticker Symbol FOLD
Full Company Profile

Financial Performance

In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for FOLD stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 99.53% from the latest price.

Price Target
$17.0
(99.53% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)

Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving...

9 days ago - Seeking Alpha

In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer

Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al. Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al.

20 days ago - GlobeNewsWire

NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act

Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al.

23 days ago - GlobeNewsWire

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...

27 days ago - GlobeNewsWire

Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - Pres...

5 weeks ago - Seeking Alpha

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webc...

5 weeks ago - GlobeNewsWire

Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. (NASDAQ: FOLD) brea...

5 weeks ago - GlobeNewsWire

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 202...

6 weeks ago - GlobeNewsWire

Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025

PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at th...

7 weeks ago - GlobeNewsWire

NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement Cases

Cornelius Campbell Burgess v. Administrative Law Judge Jennifer Whang, Federal Deposit Insurance Corp., Acting Chairman Martin J. Gruenberg, Director Michael J. Hsu, Director Rohit Chopra Cornelius Ca...

2 months ago - GlobeNewsWire

NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined

Merrick Garland, Attorney General of the United States, et al. v. Texas Top Cop Shop, Inc., et al. Merrick Garland, Attorney General of the United States, et al. v. Texas Top Cop Shop, Inc., et al.

2 months ago - GlobeNewsWire

3 Oversold Biotech Names

High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t...

Other symbols: AVDLJAZZVKTXXBI
2 months ago - Seeking Alpha

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1

2 months ago - GlobeNewsWire

Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P....

2 months ago - GlobeNewsWire

Fold, Inc. Announces Up To $30 Million Convertible Note Financing Backed by Bitcoin

NEW YORK--(BUSINESS WIRE)--Fold, Inc. (“Fold” or the “Company”), a pioneering bitcoin financial services company, today announced that it has closed a $20 million convertible note financing from ATW P...

3 months ago - Business Wire

Amicus Therapeutics: Cheap Heading Into 2025

Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and P...

3 months ago - Seeking Alpha

NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It

Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food an...

3 months ago - GlobeNewsWire

NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act

Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al.

3 months ago - GlobeNewsWire

Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension

The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et al. The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et ...

3 months ago - GlobeNewsWire

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settl...

Other symbols: IMRX
3 months ago - Benzinga

NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial

Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al. Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al.

4 months ago - GlobeNewsWire

NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial Rights

Saul Ortega & David Rogers v. Office of the Comptroller of the Currency Saul Ortega & David Rogers v. Office of the Comptroller of the Currency

4 months ago - GlobeNewsWire

Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Marte...

5 months ago - Seeking Alpha

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...

5 months ago - GlobeNewsWire

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024

PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024...

5 months ago - GlobeNewsWire